Family Medicine·West Reading, PA

Tower Health/Reading Hospital

Signal lift68%88%+20 pp with a signal here
Allocate signal →Track an away here25-26 cycle · applicant-level
Step 2 invited
225–256
p10 – p90
Sample N
1,110
applicants this cycle
This cycle
no tracked aways yet
Match rate
0.6%
7 of 152 applicants
01Cohort funnelthis cycle
N = 1,110
Applied
1,110
100.0%
Invited
152
13.7%
Class size
7
0.6%
J-1 visaDO recognizedCategorical
Your fitTower Health/Reading Hospital Program

Create a free profile to see your personalized fit

Get started
Contact
JS
Program Director
Jacqueline Leigh Storer, DO
Email director
JM
Program Coordinator
Jenna Moore, MBA
Email coordinator
Training sites2 hospitals · West Reading
  • 1
    Tower Health
    West Reading, PA
    Primary
  • 2
    Reading Hospital
    West Reading, PA
    Participant
Score rangesinvited cohort
USMLE Step 2 CK225256
180205230255280
COMLEX Level 2 CE444600
400500600700800
Interview rates
US MD
73%
US DO
53%
US IMG
11%
Non-US IMG
4%
Applicant origin
In-state
58%
Out-of-state
12%
Interview prepFamily Medicine
specialtyWhat attracts you to the breadth of family medicine?★ common
programRural vs urban practice — what's your preference?
clinicalHow do you approach continuity of care?
specialtyTell me about procedures you'd like to incorporate into your practice.
personalTell me about yourself.★ common
specialtyWhy did you choose this specialty?★ common
programWhy are you interested in our program?★ common
behavioralWhat are your strengths and weaknesses?★ common
personalWhere do you see yourself in 5-10 years?★ common
Community resourcesFamily Medicine · 25-26
Save this program

Add Tower Health/Reading Hospital to your list

Build a personal match list. Compare programs side-by-side, see how your timing stacks against peers, and get notified when peers hear back.

Next

Calculate your match probability for Family Medicine.

See how your profile compares across all programs.

Open calculator →

Data from NRMP 2025 Residency Explorer. Not medical advice. © 2026 Rezumab LLC.